Twist Bioscience Corporation (TWST) Fair Value 2026

TWST · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.4 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-08-28, Twist Bioscience Corporation (TWST) trades at $141.38. QOC: 7.4/10. Value Trap Risk: 12/100 (SAFE). 0/13 models active.

Key Facts

Ticker
TWST
Price
$141.38
Quality Score
7.4/10
Value Trap Risk
12/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give TWST?

0 Intrinsic Value Models vs. Current Price ($141.38)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Twist Bioscience Corporation (TWST) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Twist Bioscience Corporation currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About TWST?

0 of 13 models are currently active for TWST. See which stocks rank higher →

How Does TWST Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, TWST ranks #20 by Quality of Company score. CirclFi's QOC score of 7.4/10 evaluates 32 fundamental signals. A score of 7.4 indicates above-average quality.

Twist Bioscience Corporation's positioning within the Diagnostics & Research segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.

Is TWST a Value Trap?

CirclFi's Value Trap algorithm assigns TWST a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Twist Bioscience Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Twist Bioscience Corporation earns a quality score of 7.4/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TWST valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Twist Bioscience Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

CSTLCastle Biosciences, Inc.QOC 7.4CDNACareDx, Inc.QOC 7.3RVTYRevvity, Inc.QOC 7.4ADPTAdaptive Biotechnologies CorporationQOC 7.2NTRANatera, Inc.QOC 7.5GHGuardant Health, Inc.QOC 7.0PSNLPersonalis, Inc.QOC 6.4NSTMNovelStem International Corp.QOC 4.2IQVIQVIA Holdings Inc.QOC 8.3IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: CSTL · CDNA · RVTY · ADPT · NTRA · GH · PSNL · NSTM · IQV · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to TWST?

7 companies across all industries closest to TWST’s Quality of Company score of 7.4/10.

GDSGDS Holdings LimitedQOC 7.4ASLEAerSale CorporationQOC 7.4JGAurora Mobile LimitedQOC 7.4LENLennar CorporationQOC 7.4KIMKimco Realty CorporationQOC 7.4SRBKSR Bancorp, Inc.QOC 7.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GDS · ASLE · JG · LEN · KIM · SRBK · NVDA

What Else Do Investors Ask About Twist Bioscience Corporation’s Valuation?

What is Twist Bioscience Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Twist Bioscience Corporation (TWST). The Quality of Company score is 7.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TWST overvalued or undervalued right now?

At $141.38, 0 of 0 active models suggest TWST may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Twist Bioscience Corporation's business model in Diagnostics & Research.

What does a Quality of Company score of 7.4 mean for TWST?

Twist Bioscience Corporation's QOC of 7.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on TWST?

CirclFi analyzes TWST with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is TWST a value trap in 2026?

Twist Bioscience Corporation's Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Twist Bioscience Corporation (TWST) a Quality of Company score of 7.4/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/TWST/ · Methodology
Primary sources for this TWST valuation
  • Financial statements: Twist Bioscience Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001581280) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TWST as of ; valuations recomputed .